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Abstract
Background: The Mouse Genomes Project is an ongoing collaborative effort to sequence the genomes of the
common laboratory mouse strains. In 2011, the initial analysis of sequence variation across 17 strains found 56.7 M
unique single nucleotide polymorphisms (SNPs) and 8.8 M indels. We carry out deep sequencing of 13 additional
inbred strains (BUB/BnJ, C57BL/10J, C57BR/cdJ, C58/J, DBA/1J, I/LnJ, KK/HiJ, MOLF/EiJ, NZB/B1NJ, NZW/LacJ, RF/J,
SEA/GnJ and ST/bJ), cataloguing molecular variation within and across the strains. These strains include important
models for immune response, leukaemia, age-related hearing loss and rheumatoid arthritis. We now have several
examples of fully sequenced closely related strains that are divergent for several disease phenotypes.
Results: Approximately 27.4 M unique SNPs and 5 M indels are identified across these strains compared to the
C57BL/6 J reference genome (GRCm38). The amount of variation found in the inbred laboratory mouse genome
has increased to 71 M SNPs and 12 M indels. We investigate the genetic basis of highly penetrant cancer susceptibility
in RF/J finding private novel missense mutations in DNA damage repair and highly cancer associated genes. We use
two highly related strains (DBA/1J and DBA/2J) to investigate the genetic basis of collagen-induced arthritis
susceptibility.
Conclusions: This paper significantly expands the catalogue of fully sequenced laboratory mouse strains and now
contains several examples of highly genetically similar strains with divergent phenotypes. We show how studying
private missense mutations can lead to insights into the genetic mechanism for a highly penetrant phenotype.
Keywords: Sequencing, Mouse genomes, Laboratory mouse, Genomic variation, Disease, Cancer, arthritis,
Biological pathways
Background
Genetic mutations (such as single nucleotide polymor-
phisms (SNPs), indels and structural variants (SVs)) are
commonly involved in the dysregulation of normal gene
function and frequently the cause of human diseases.
Laboratory mouse strains are one of the primary model
organisms used to study human disease and have
excelled as a model system in which to identify and
characterise the role that genomic variation plays in sus-
ceptibility and pathogenesis [1, 2]. A multitude of inbred
laboratory strains are now commonly employed in the
examination of a wide range of human diseases [3].
The first draft version of the mouse reference genome
was produced based on a whole genome shotgun se-
quencing strategy of a female C57BL/6J strain mouse [4]
followed several years later by the finished genome
sequence [5]. The mouse reference genome enabled a
whole set of new applications and technologies such as
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many new genetic screens [6], the creation of null alleles
for the majority of genes [7], and accelerated the discov-
ery of genetic diversity in other laboratory mouse strains
[8]. The Mouse Genomes Project (MGP) was initiated
with the primary goals to sequence the genomes of the
common laboratory mouse strains, catalogue molecular
variation and produce full chromosome sequences of
each strain [9]. The initial phase of the MGP focused on
sequencing and variation analysis of a representative
subset of the most commonly used inbred mouse strains.
This culminated in the identification of 57.7 M SNPs,
8.8 M indels and 0.71 M SVs across the genomes of 17
of the most commonly used strains [9].
Here, we present a significant expansion of the MGP
variation catalogue by deep sequencing (30–60×) and
variation analysis of 13 strains: BUB/BnJ, C57BL/10J,
C57BR/cdJ, C58/J, DBA/1J, I/LnJ, KK/HiJ, MOLF/EiJ,
NZB/B1NJ, NZW/LacJ, RF/J, SEA/GnJ and ST/bJ. These
represent a diverse set of phenotypes and genotypes of
inbred mouse strains that are commonly used to study
rheumatoid arthritis (RA) (DBA/1J), diabetes (KK/HiJ),
immunity (C57BL/10J, NZB/B1NJ, NZW/LacJ), cancer
(C58/J, RF/J), development (I/LnJ, SEA/GnJ) and age-
related diseases (BUB/BnJ, C57BR/cdJ, MOLF/EiJ, ST/
bJ). The catalogue of variants derived from these strains
has been incorporated into the current MGP variation
catalogue to determine private and shared variation
among the 13 strains and refine private variation identi-
fication across all strains in the catalogue.
We also demonstrate how variants in these 13 strains
can be utilised to investigate the genetic basis of disease.
In the first analysis, predicted damaging SNPs private to
the RF/J strain were used to identify candidate genes
and biological pathways involved in tumorigenesis and
disease progression. The RF/J strain is an important
model in cancer studies due to a naturally high predis-
position to several cancers including acute myeloid
leukaemia and thymic lymphoma [10, 11]. The second
analysis involved the identification of candidate genes
for collagen-induced arthritis (CIA) susceptibility, a
model of human RA, by comparison of SNPs between
two genetically related strains with divergent pheno-
types. Candidate genes identified in the analysis of these
two strains, DBA/1J (susceptible) and DBA/2J (resistant),
were then further investigated to identify potential
causal pathways and biological processes controlling
pathogenesis of this disease.
Results and discussion
A phenotypically diverse set of laboratory mouse strains
A total of 13 genetically and phenotypically diverse
inbred laboratory mouse strains were chosen for analysis
in the current study (Fig. 1). These strains were selected
from across the inbred mouse subspecies groups and
represent a large number of model systems used to study
human disease. This dataset includes strains that are
genetically similar to the current MGP strains, such as
DBA/1J and C57BL/10J, as well as strains that are
genetically divergent, such as the wild-derived Japanese
strain MOLF/EiJ (Fig. 1).
With this expansion, there are now several examples of
fully sequenced strains which are closely related to other
strains in the catalogue but are divergent for disease phe-
notypes. For example, C57BR/cdJ mice are closely related
to the mouse reference genome strain C57BL/6, but
display different patterns of learning behaviour [12]. Fol-
lowing avoidance training, C57BL/6 mice exhibit poor
conditioned avoidance performance, whereas C57BR/cdJ
perform much better in avoidance tests [13]. Another ex-
ample of genetically similar but phenotypically divergent
strains include DBA/1J and DBA/2J which are susceptible
and resistant, respectively, to CIA. DBA/1J mice are
commonly used as a model for RA and exhibit several
similarities to the human disease including synovitis and
degradation of the bone and cartilage tissue [14].
Among this expansion of the variation catalogue are
several strains with similar phenotypes such as the NZB/
B1NJ and NZW/LacJ strains. These strains are widely used
as models for autoimmune abnormalities. For example,
both strains develop anti-DNA antibodies. Also, F1 hy-
brids of these two strains develop an autoimmune disease
resembling human systemic lupus erythematosus [15].
Another interesting addition to the variation catalogue
examined here is the RF/J strain [10, 11]. This strain is an
important model for cancer research due to a naturally
high incidence rate of acute myeloid leukaemia and
tumour development. This strain also exhibits a high
spontaneous rate of glomerular hyalinisation and glomer-
ulosclerosis [16]. Each of the remaining strains also exhibit
several notable phenotypes; BUB/BnJ are homozygous for
the Mass1frings allele, which is responsible for early onset
(3–4 weeks of age) hearing impairment [17]; a high
proportion of I/LnJ mice display agenesis of the corpus
callosum which is associated with developmental delays
and impaired motor function in humans [18]; SEA/GnJ
mice segregate for the short ear allele (BMP5se), which
causes numerous defects in cartilage and bone tissue [19];
both the ST/bJ and MOLF/EiJ strains are homozygous for
the retinal degeneration allele Pde6brd1 [20] (11853768);
and C58/J and KK/HiJ mice are homozygous for the
age-related hearing loss mutation Cdh23ahl [21].
Identification of SNPs and indels
The 13 mouse strains were sequenced to a mapped
depth of 30–60× on the Illumina HiSeq platform at a
read length of 101 bp paired-end (Table 1). In total, over
1.8 Tb of raw sequencing data were generated. All raw
sequencing reads are available from the European
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Nucleotide Archive (ERP000927; see Table S1 in Additional
file 1). Sequencing reads were aligned to the GRCm38
mouse reference genome using BWA-mem, followed by a
local realignment around indels using GATK. The
aligned sequence reads are also available from the MGP
(ftp://ftp-mouse.sanger.ac.uk).
A total of 27.39 M high confidence homozygous SNPs
were identified across the genomes of 13 inbred labora-
tory mouse strains (Fig. 1). This catalogue of variants,
when compared to the MGP variation catalogue of 23
strains, contains 2.78 M (10.15 %) novel variant sites, of
which 2.33 M (8.51 %) are private to one of the 13
Table 1 Sequencing, alignment and variant statistics
Strain Raw bases (Gb) Mapped coverage SNPs Private Indels Private SVs Private
BUB/BnJ 135.42 38.92 4,982,043 54,418 929,617 19,187 37,034 5375
C57BL/10J 108.43 29.85 349,702 2733 83,930 1893 12,939 9904
C57BR/cdJ 140.94 39.76 2,601,138 9683 485,803 6307 18,927 3462
C58/J 153.06 43.76 2,834,841 27,805 547,151 11,726 20,666 3777
DBA/1J 139.79 38.55 5,129,920 9001 955,621 9684 34,239 4480
I/LnJ 124.97 34.11 5,547,267 78,583 1,013,686 24,628 36,612 6342
KK/HiJ 151.60 44.42 5,893,784 94,110 1,078,555 31,084 36,588 3725
MOLF/EiJ 112.55 30.68 19,027,669 1,818,029 2,892,638 367,208 79,239 17,394
NZB/B1NJ 133.24 36.15 5,473,276 54,189 1,014,782 20,670 34,406 3164
NZW/LacJ 160.46 49.06 5,736,044 52,902 1,051,170 21,397 38,207 3308
RF/J 147.33 43.18 5,090,115 32,390 937,091 13,440 44,205 11,685
SEA/GnJ 134.23 38.67 4,603,720 30,263 857,599 12,729 33,033 3686
ST/Bj 223.17 63.74 5,107,777 70,064 978,238 24,325 37,350 4474
Total sequencing in Gigabases (Gb), mapped coverage (based on 3Gb genome) and the total and private number of SNPs, indels and large deletions is shown
Fig. 1 Phenotypes and variant statistics for each of the 13 strains. The strains sequenced in this project with a short description and notable phenotypes,
followed by the total number of SNPs, indels and large deletions. Individual strain images provided by The Jackson Laboratory (ME, USA). The phylogenetic
tree is a genome-wide summary built using all of the HapMap genotypes for each strain [22] and does not reflect local haplotype structure
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strains in this study when compared to the entire
variation catalogue (Fig. 2; Additional file 2). The wild-
derived MOLF/EiJ strain contained the most individual
variation both in terms of total (19.03 M) and private
SNPs (1.82 M). Conversely, the C57BL/10J strain, which
is genetically much more similar to the reference gen-
ome, displayed the least amount of total and private
variation (349,702 and 2733). The total number of SNPs
and short indels shared between each pair of strains
contained in the MGP variation catalogue is given in
Additional file 3.
In total 4.81 M high quality homozygous indels were
identified, 0.64 M of which are novel indels sites and
0.56 M of these are private to one of the 13 strains when
compared to the all other strains included in the MGP
variation catalogue (Fig. 2; Additional file 2). The size
of the 2.91 M deletions identified is in the range of
1–46 bp and the size of 2.5 M insertions is in the
range of 1–29 bp. Similar to the number of SNPs
identified, MOLF/EiJ contained the largest number of
short indels relative to the reference genome (2.89 M
total and 367,208 private). Additional comparisons of
the total number of indels shared between each pair
of strains is contained in Additional file 3.
To ensure the accuracy of our SNP calling pipeline,
genotypes from the mouse HapMap [22] for approxi-
mately 138,000 locations were obtained and compared
to the corresponding genotypes in each of the 13 strains
involved in this study. After removing missing genotypes
and mapping genotype locations from NCBIm37 to
GRCm38 of the reference genome, between 115,572
(MOLF/EiJ) and 129,825 (C58/J) genotypes remained for
comparison with each strain. Sensitivity of our calling
pipeline was determined by assessing the concordance
rate for each of the individual strains. Greater than
98 % of genotypes were concordant for each of the
individual strains (Additional file 4). In fact, a total of
1.64 M genotypes were compared, in which 1.62 M
(98.68 %) were concordant. All of the variants in this study
were incorporated into the MGP v5 variation catalogue
and are available from the project website (ftp://ftp-mou-
se.sanger.ac.uk) and the European Variation Archive
(PRJEB11471). The MGP v5 catalogue comprises 36
inbred laboratory strains with 70.72 M SNP sites, 39.23 M
of which are private to an individual strain, and 11.29 M
short indels, 6 M of which are private.
Functional consequences of SNPs and indels
The Variant Effect Predictor (VEP) tool [23] was used
to assign functional annotations to the SNP and indel
variants across the 13 strains (Table 2 and Additional
file 5). The majority of SNPs are found in intergenic
(46.58–52.28 % across strains; 50.57 % of all SNPs identi-
fied) and intronic (15.74–18.58 %; 18.08 %) regions.
Additionally, a large amount of variation was identified up-
and downstream of protein-coding genes (3.91–4.47 %;
3.93 % and 3.79–4.43 %; 4.05 %, respectively), and within
the 3’ (0.20–0.24 %) and 5’ (0.02–0.04 %) untranslated
regions (UTR).
Although most SNPs were found in non-coding re-
gions, a large amount of variation was located in
protein-coding regions (76,108 SNPs). Of particular note
are SNPs that affect the protein-coding sequence, such
as splice variants and non-synonymous SNPs. A total of
27,416 (0.1 %) missense SNPs were identified across the
13 strains. MOLF/EiJ contained the largest number of
missense variants (17,311); however, only 2288 of these
were private to this strain. One particular novel missense
mutation is a G→A transition in exon 4 of the Pctp
gene identified in the NZW/LacJ and NZB/BlNJ strains.
This mutation, at position 89,987,348 on chromosome
11, is also shared with the NZO/HlLtJ strain which sug-
gests fixation of the mutation in progenitor mice prior
to development of the NZ inbred mouse strains [24].
This mutation causes an arginine to histidine change at
amino acid position 120, which leads to inactivation of
the protein. Although the physiological implications of
inactivating Pctp are not yet fully understood, inactiva-
tion has been linked to changes in control of hepatic
cholesterol homeostasis [25] and impaired biliary lipid
secretion [26].
We identified 178 SNPs that result in a stop gain or
loss. MOLF/EiJ contained the most individual variation
in coding regions including 23 stop losses and 85 stop
gains; however only one stop loss and 18 stop gain vari-
ants were private to this strain. C57BL/10J was the only
strain in which a stop gain or loss was not identified.
Several mouse strains are known to carry homozygous
mutations that lead to the introduction of a premature
stop in the coding sequence. Among the list of stop
gains identified in our study was a C→A mutation
which causes a premature stop codon in the Pde6b gene
on chromosome 5 at position 108,421,265. This mutation
is found in several strains included in the MGP variation
catalogue, including three from this study: BUB/BnJ,
MOLF/EiJ and ST/bJ. This mutation, rs49995481, results
in truncation of the predicted protein in which over
half of the protein is missing and is known to cause
early onset severe retinal degeneration [27].
To determine the impact of an amino acid substitu-
tion, SIFT (Sorting Intolerant from Tolerant) [28] and
grantham matrix scores (GMS) [29] were estimated for
all non-synonymous SNPs. SIFT scores ≤ 0.05 are usually
considered to be indicative of a deleterious mutation.
Although most non-synonymous SNPs are tolerated,
11,182 in 6241 genes were predicted to have a deleteri-
ous effect. Similar to SIFT, GMS enables the identifica-
tion of moderately radical (100 < GMS ≤ 150) and radical
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Fig. 2 SNP, indel and SV densities for chromosome 1 of all strains. SNP, indel and SV (insertions and deletions) densities (per MB) for all variants
identified on chromosome 1 for each of the 13 strains
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(GMS > 150) non-synonymous substitutions. Only 3337
(10.78 %) of non-synonymous substitutions are consid-
ered radical using GMS, although 1130 of these are also
annotated as deleterious using SIFT.
Similar to SNPs, most indels are intergenic (47.76 %),
intronic (18.82 %) or within 5 kb upstream (4.26 %) or
downstream (4.27 %) of a coding gene. Although, in
general, indels found in intergenic or intronic regions
are not known to have an effect on protein-coding
genes, several strains carry a 5 bp deletion at the branch-
ing point of intron 7 of the Il3ra gene which leads to
skipping of exon 8 [30]. This mutation, on chromosome
14 at position 14,350,904, is found in nine MGP strains
including five from this study: BUB/BnJ, C58/J, I/LnJ,
NZB/BlNJ and RF/J. A small number of indels cause an
in-frame deletion (368) or insertion (278) and only 308
indels cause a frameshift. As with missense SNPs,
MOLF/EiJ contained the largest number of frameshift
mutations (172); however, proportional to the total num-
ber of indels identified in this strain, this number was
approximately the same as the other strains (0.0006 %).
Several strains are known to carry indels that affect the
protein-coding function of genes, such as a known TA
deletion in the haemolytic complement gene. This dele-
tion, at position 35,043,207 on chromosome 2, leads to
the creation of a premature stop codon 4 bases after the
deletion [31] and consequently macrophages from mice
carrying this mutation fail to secrete complement 5 (C5)
[32]. This mutation is carried by several strains in the
MGP catalogue, including six strains from this study:
I/LnJ, KK/HiJ, MOLF/EiJ, NZB/B1NJ, RF/J and ST/bJ.
Mice deficient for C5 have previously demonstrated
enhanced protection against development of severe
glaucoma compared to mice of the same strain suffi-
cient for C5 [33].
Novel and private variation
To identify variants unique to an individual strain (pri-
vate SNPs and indels), genotypes for all variant sites
identified in each of the 13 strains were computationally
derived for all strains in the MGP variation catalogue
(36 strains). Private SNPs were then identified as high
quality homozygous alternative sites, in which the same
site must be a high quality homozygous reference allele
in at least 30 other strains. A maximum of five strains
were allowed a missing genotype or low quality call at
the same site to account for the genetic diversity of
wild-derived strains in the MGP variation catalogue.
This resulted in 2.33 M (8.52 %) private SNPs across the
13 strains, although 1.82 M of these private sites were
identified in the wild-derived MOLF/EiJ strain (Table 1).
This accounted for 9.56 % of all MOLF/EiJ SNP sites,
which was much higher than the proportion of private
variation identified for any of the other 12 strains
(0.18–1.6 %) (Table 1). DBA/1J had the lowest proportion
of private SNPs due to the genetic similarity of DBA/1J
and DBA/2J [34]; 90.72 % of DBA/1J SNPs are shared
with DBA/2J.
Similar to the total variation per strain, most private
SNPs are located in intergenic (45.67–57.68 % per strain)
and intronic regions (13.28–23.32 %) while 7.18–10.3 %
per strain are within 5 kb of a coding gene. In total,
7237 private missense SNPs were identified in 4615
genes across all 13 strains although 4086 of these are es-
timated to have more than one consequence (Additional
file 6). Most private missense SNPs are predicted to be
Table 2 Predicted consequences of variants
SNPs Indels Exonic SVs
Strain Synonymous Non-synonymous Stop gain/loss Frameshift variant Inframe variant Deletions Insertions
BUB/BnJ 9751 6050 44 41 169 1247 720
C57BL/10J 581 298 0 4 8 57 102
C57BR/cdJ 4400 2948 18 26 52 288 227
C58/J 5238 3362 23 35 69 330 254
DBA/1J 9782 6198 39 53 149 419 389
I/LnJ 10389 6249 42 52 150 690 1671
KK/HiJ 10816 6197 50 56 140 599 462
MOLF/EiJ 33710 17,311 108 172 439 897 1305
NZB/B1NJ 10403 6367 43 62 146 500 390
NZW/LacJ 10434 6326 46 61 146 673 425
RF/J 9891 6174 39 56 140 2033 862
SEA/GnJ 9309 6027 38 57 138 1284 614
ST/bJ 9021 5578 45 59 133 713 413
Doran et al. Genome Biology  (2016) 17:167 Page 6 of 16
tolerated by SIFT or have a GMS < 100. Using SIFT pre-
dictions, 2146 SNPs affecting 1768 genes were predicted
to be deleterious. Similarly, using GMS predictions, only
893 SNPs affecting 818 genes were predicted to cause
moderate changes and 461 SNPs affecting 446 genes
were predicted to cause radical changes to the CDS. As
expected, only a small number of private variants led to
changes in stop codons (93 stop gains and 12 stop
losses) or were predicted to affect splice acceptor or
donor sites (46 and 53 SNPs, respectively) although
many of these SNPs were predicted to have more than
one consequence (51 stop gains, 8 stop losses, 43 splice
acceptor and 43 splice donor sites).
Ninety-one genes are affected by a private stop gain.
For example, a C→ T transition at amino acid position
208 of the bone morphogenetic protein 5 (BMP5) gene
causes a stop gain private to the SEA/GnJ strain. Bone
morphogenetic proteins are signalling molecules in-
volved in the development of bone and cartilage tissue
[35]. This strain is known to be homozygous for this
mutation (also known as the short ear allele). Mice
homozygous for the short ear allele exhibit abnormal
skeletal development leading to smaller and weaker
bones, reduced shape and size of the external ear, a
reduced number of ribs and alterations in size and shape
of many small bone elements [36].
Nearly half of private indels (48.96 %) are found in
intergenic regions, 18.61 % are intronic and 8.89 % are
within 5 kbp of a coding gene while almost one-quarter
(23.27 %) of indels are predicted to have two or more
consequences. Only 84 (0.015 %) private frameshift mu-
tations were identified, and 61 of these were identified in
MOLF/EiJ. As expected, very little private variation was
observed in the C57BL/10J strain compared to the
C57BL/6J reference genome. These two strains were
separated in 1921 from the same C57BL progenitor col-
ony and no other strains are known to have contributed
to the parentage of either strain [3]. Eighty-three genes
were identified that carry a private frameshift mutation
in one of the 13 strains such as a ‘T’ insertion resulting
in a frameshift at amino acid position 431 of the phos-
phorylase kinase alpha 1 (Phka1) gene. This mutation,
which is private to the I/LnJ strain, causes a premature
stop codon in the downstream coding region resulting
in a great reduction of Phka1 transcript in skeletal
muscle and partial reduction in heart and brain [37].
Additionally, this mutation has been implicated in
myopathy and glycogen storage disease in both humans
and mice [38].
Large structural deletions and insertions
A total of 79,943 large (>100 bp) deletions and 143,854
insertions were identified across all of the strains
(Table 1). Of the large deletions identified, 20,122 were
novel and a large proportion (17,514) of these were
private to one of the 13 strains when compared to the
full variation catalogue of 36 strains. Structural variant
insertions were also identified for all strains in the MGP
variation catalogue, including the 13 strains from this
study. A total of 143,854 insertions were identified
across the 13 strains examined in this study. Approxi-
mately 48.34 % of these were novel (69,542), 63,262 of
which were private to one of the 13 strains when
compared to the MGP variation catalogue.
To assess the accuracy of our calling pipeline, poly-
merase chain reaction (PCR) validation deletions and
insertions were obtained for seven MGP strains [39].
Structural variants were identified in these seven strains
using the same approach as for the 13 strains in this
study. Sensitivity estimates were estimated for each of
the seven strains (Table S2 of Additional file 1). All
sensitivity estimates for each strain were between
92.05–94.12 % for deletions and 81.94–94.25 % for in-
sertions, which are comparable to estimates previously
published for MGP strains [40, 41].
Although none of the 13 strains included in this study
were among the seven strains, 151 PCR-validated dele-
tions and 84 insertions were available for the DBA/2J
strain. The 151 PCR-validated deletions identified in the
DBA/2J strain [39] were compared with the deletion call
set identified in DBA/1J. Although these are two separ-
ate strains, they are genetically identical at many loci
throughout the genome. Most of the 151 deletions
overlapped with a deletion identified in DBA/1J from
our analysis (131). This meant that 20 deletions PCR-
validated in DBA/2J were not identified in the DBA/1J
strain. Upon visual inspection of these deletions using
the alignment data and the integrative genomics viewer
[42], eight were identified as real differences between the
strains. When true structural variant differences between
the strains are removed from the sensitivity analysis,
the sensitivity increases to 91.61 % (131/143) which is
similar to the proportion of SNP sites that are identical
between the strains (90.72 %).
Sensitivity estimates were also calculated for SV inser-
tions identified in the DBA/1J strain using PCR-validated
calls identified in the DBA/2J strain. Most DBA/2J
insertions were also identified in DBA/1J (76/84). Similar
to deletions, sensitivity (90.48 %) of the SV insertion call-
ing pipeline was similar to estimates reported previously
in MGP strains [40, 41].
Little is known about structural variation in the ge-
nomes of the 13 strains included in this study. However,
many of the structural variants which we identified were
also shared with another strain in the MGP variation
catalogue. For example, a 6-kb deletion in BFSP2 which
results in alterations of optical lens quality has previ-
ously been identified in the FVB/NJ and 129 strains [43].
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From our analysis, we identified this mutation in both
the NZB/B1NJ and NZW/LacJ strains. Although neither
of these strains are known models for examining optical
lens quality, utilising either strain in studies which may
rely on vision or lens quality could lead to spurious
results.
Coding sequences for all genes annotated to the
mouse genome were then compared against our deletion
call set to identify genes which may have their function
disrupted. A total of 4954 structural deletions over-
lapped the coding sequence of 3316 genes. Of these,
2462 were novel and 2110 were private to one of the 13
strains in our study. Similarly, 4620 structural insertions
overlapped the coding sequence of 5076 genes, many of
which were either novel (2557) or private (2366) to one
of the 13 strains.
RF/J strain enriched for private missense variants in
cancer susceptibility genes
To investigate the potential biological mechanisms under-
lying disease phenotypes for which these strains are used
to study, two analyses were carried out. The first study
focused on the RF/J strain, which was developed at the
Rockefeller Institute through breeding of the A, R and S
strains [44]. Due to the natural predisposition of RF/J mice
to develop myeloid leukaemia, thymic lymphoma and
reticulum cell sarcomas [44], this strain is an important
model used to study cancer onset, progression and
pathogenesis. This strain also has a propensity to
develop lung, ovary and hematopoietic tumours. In
particular, this strain is widely used to study the effects
of radiation-induced myeloid leukaemia due to its high
induction rate (between 50–90 %) [44].
To identify and prioritise candidate genes for further
analysis, only genes which contained at least one mis-
sense variant private to the RF/J strain were considered
for further analysis. A total of 122 genes were identified
which met this condition (Additional file 7). Several of
the genes in this list, such as Adam15 [45], Cdh1 [46],
Msh3 and Kit [47], are known candidates for roles in
tumorigenesis and cancer pathogenesis. For example,
mice nullizygous for the Msh3 gene are reported to have
a significantly higher spontaneous incidence rate of tu-
mours than wild-type counterparts [48]. The Msh3 gene
is involved in the DNA repair mechanism, and plays an
important role in mismatch recognition [49]. The mis-
match repair pathway identifies and eliminates errors
that arise during DNA replication and defects in this
mechanism can lead to the accumulation of mutations
and cancer [50]. In fact, loss or silencing of the Msh3
gene has been reported to frequently occur in several
human cancers including lung [51] and breast [52]. In
addition, associations of mutations in the Msh3 gene to
colon [53] and prostate [54] cancer in humans have been
reported.
Another gene involved in the DNA damage response,
PALB2, was also identified in our candidate set. Muta-
tions of this gene are known to increase risk of several
cancers including breast [55] and pancreatic cancer [56].
Mutations of PALB2 are commonly identified in patients
with Fanconi anaemia. In fact, patients with PALB2-re-
lated Fanconi anaemia also have an increased predispos-
ition to malignancies associated with acute myeloid
leukaemia [57] and Wilms tumours [58]. Interestingly,
the WT1 (Wilms tumour) gene was also identified in our
candidate gene set as carrying a private missense SNP.
Additional genes of particular note in our candidate
set included the tumour suppressor gene Cdh1, muta-
tions in which are known to predispose to a wide range
of cancer types [59], and the Fas gene. Fas, a member of
the tumour necrosis factor (TNF) receptor family of pro-
teins, plays a key role in activation of apoptosis and has
been implicated in the pathogenesis of several malignan-
cies [60]. Dysregulation of apoptosis-related pathways is
also commonly observed in cancer and defects of this
signalling process are known to contribute to drug ther-
apy insensitive tumours [61]. Furthermore, polymor-
phisms in the promoter of the Fas gene have been
associated with an increased risk of developing acute
myeloid leukaemia in humans [62]. Interestingly, follow-
ing γ-irradiation-induced thymic lymphoma, Fas expres-
sion has also been shown to be lower in the RF/J strain
compared to the SPRET/EiJ and BALB/cJ strains, both
of which are known to be more resistant to this induced
phenotype [63]. Although no private missense SNPs in
this gene were identified in the BALB/cJ strain, one
missense SNP in exon 2 was identified. Similarly, 17
missense SNPs were identified in the wild-derived
SPRET/EiJ strain, 14 of which were private to this strain.
Due to each of the abovementioned strains containing
missense SNPs in this gene, it is difficult to determine
the exact role this gene or mutations in this gene may
play in the pathogenesis of cancer phenotypes observed
in the RF/J strain.
To examine the overall effect of private missense muta-
tions in RF/J, we identified biological pathways over-
represented in this gene set. Significantly over-represented
REACTOME [64] and KEGG [65] pathways were identi-
fied using the hypergeometric test available through the
pathway over-representation analysis tools at InnateDB
[66]. After correcting p values using the Benjamini–Hoch-
berg method, four pathways were significantly over-
represented (p < 0.05). Notably, this list included the
KEGG pathway ‘Pathways in cancer’ (p = 0.046). Each of
the remaining three significantly over-represented path-
ways were related to extracellular matrix (ECM) functions
(Table 3). In fact, the most significantly over-represented
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REACTOME and KEGG pathways were ‘Degradation of
the extracellular matrix’ (p = 0.0049) and ‘ECM-receptor
interaction’ (p = 0.013), respectively.
The ECM is a fundamental component of the cellular
microenvironment, composed of a complex mix of
structural and functional molecules [67]. The ECM has
important roles in a diverse set of functions including
cellular development, tissue differentiation, growth and
tissue homeostasis [68]. In addition, components of the
ECM are in continual contact with epithelial cells and
mediate signalling of processes involved in regulation of
cell proliferation, apoptosis and differentiation [69].
Notably, ‘ECM-receptor interaction’ has previously been
found to be enriched for genes differentially regulated in
cancer cell lines compared to normal tissue [70] and in
tumour expression patterns compared to normal tissue
[71]. In addition, abnormal ECM has been implicated in
the progression of cancer. In fact, altered ECM is com-
monly found in patients with cancer [72].
To investigate whether these results may be due to an
annotation bias within KEGG or REACTOME, the same
pathway over-representation analysis was performed
for each of the 13 strains’ private missense mutations
(Additional file 8). No strain’s gene set was enriched for
genes involved in ‘Pathways in cancer’, ‘Degradation of the
extracellular matrix’ or ‘Extracellular matrix organization’.
However, ‘ECM-receptor interaction’ was also significantly
over-represented in the MOLF/EiJ gene set (p = 0.0026).
However, it may not be appropriate to carry out such
analysis using wild-derived strains such as MOLF/EiJ due
to the relatively low representation of wild-derived strains
in the MPG catalogue compared to the classical inbred
strains. For example, approximately 56 times as many
private SNPs were identified in MOLF/EiJ compared to
RF/J (Table 1). Consequently, there are nearly 28 times as
many genes which met the inclusion criteria using
MOLF/EiJ (3366 genes) when compared to the RF/J gene
set (122 genes).
CIA candidate genes and biological pathways
The second study carried out focused on the genetic and
phenotypic differences between the genetically similar
DBA/1J and DBA/2J strains. The DBA strain was
developed by Clarence C. Little in 1909 and is the oldest
of all inbred mouse strains. During 1929 and 1930,
crosses between substrains led to the establishment of
several new substrains including DBA/1J and DBA/2J
[34]. Just over 90.72 % of SNP sites identified in the
DBA/1J strain are identical to the DBA/2J strain; how-
ever, these strains exhibit several phenotypic differences
including total body weight and body fat weight [73]. In
addition, differences in circulating plasma levels of
triglycerides, high-density lipoprotein, leptin and insulin
have been reported between DBA/1J and DBA/2J [34].
Notably, these strains also display divergent susceptibil-
ity to CIA, a model for human RA. The DBA/1J strain,
sequenced as part of this study, is susceptible to CIA
whereas the DBA/2J strain is resistant [74]. To identify
potential variation, and genes that may be involved in
these divergent phenotypes, all SNPs identified in DBA/
1J which are shared with the DBA/2J strain were re-
moved. This meant we were left with a set of DBA/
1J-specific SNPs. However, despite the genetic similar-
ity of these strains, they have different haplotypes at
the MHC locus [75]. To remove SNPs in this region not
associated with CIA susceptibility, all SNPs shared with
the CIA resistant but MHC identical FVB/NJ strain were
also removed. A total of 258,416 SNPs remained in this
DBA/1J-specific CIA susceptibility candidate set. From
this, all genes containing at least a single missense variant
with the additional SIFT annotation of ‘deleterious’
were identified (123 SNPs identified in 101 genes).
Similar to the previous study, this gene set was then
used to identify significantly over-represented biological
pathways using the tools available from InnateDB [66].
Murine CIA, a widely used model for human RA, is
characterised as an autoimmune inflammatory joint
disease which primarily affects synovial joints ultimately
leading to joint impairment and disability [14]. The
pathogenesis of RA involves the influx of both innate
and adaptive immune cells, which in turn promote
pro-inflammatory cytokine production and decreased
synthesis of anti-inflammatory cytokines [76]. Normally
the inflammatory response is balanced by the release of
anti-inflammatory molecules which prevent chronic
inflammation. Disruption of the anti-inflammatory balan-
cing mechanism can lead to sustained chronic inflamma-
tion as observed in RA. Interestingly, our list of candidate
Table 3 Significantly over-represented biological pathways and candidate genes identified in RF/J
Pathway name Database p value (corrected) Candidate genes
Degradation of the extracellular matrix REACTOME 4.91 × 10–3 Adam15, Cdh1, Col4a4, Eln, Mmp11
Extracellular matrix organization REACTOME 1.15 × 10–2 Adam15, Cdh1, Col4a4, Eln, Lama3, Mmp11
ECM-receptor interaction KEGG 1.32 × 10–2 Col4a4, Itga10, Itga7, Lama3
Pathways in cancer KEGG 4.56 × 10–2 Cdh1, Col4a4, Fas, Kit, Lama3, Msh3
Candidate genes are those that are found in the respective pathways and contained a missense SNP private to the RF/J strain. Corrected p values are based on
the Benjamini–Hochberg method
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genes containing a missense deleterious SNP also included
the anti-inflammatory mediator interleukin-10 receptor
α subunit (IL10RA). Interleukin-10 (IL10) is an anti-
inflammatory cytokine whose functions are mediated
by binding to IL10RA which in turn stimulates signalling
cascades used to inhibit production of pro-inflammatory
cytokines such as TNF-α [77]. IL-10-/- DBA/1J mice have
increased CIA severity compared to mice either homozy-
gous or heterozygous at the same locus [78]. Similarly,
therapeutic treatment with IL-10 has been shown to
suppress the development of CIA in rats [79]. In addition,
mutations in the IL10RA have been implicated in the
pathogenesis of several inflammatory autoimmune dis-
eases such as murine lupus [80] and ulcerative colitis [81].
Diminished IL10 signalling, through mutations in the
IL10RA, have been implicated in the severity of
several autoimmune diseases including inflammatory
bowel disease and arthritis [81, 82].
Similar to RF/J, pathway over-representation analysis
was carried out using the candidate gene set identified
in the DBA/1J analysis. A total of 10 pathways were
significantly over-represented (corrected p < 0.05), many
of which are related to innate immunity and inflamma-
tion signalling (Table 4). The most significantly over-
represented pathway was ‘cellular adhesion molecules
(CAMs)’ (p = 3.98 × 10–4). CAMs are expressed on the
surface of cells and play a critical role in the inflammatory
response. This pathway has been shown to be enriched
for genes with a differentially methylated signature in
synovial tissue of RA patients compared to patients
without RA [83]. Several additional KEGG pathways
identified in our analysis have also been implicated in
the pathogenesis of RA including ‘cytokine-cytokine
receptor interaction’ (p = 0.047) and ‘antigen processing
and presentation’ (p = 0.011) [84]. Notably, none of the
candidate genes identified in the cytokine-cytokine
receptor interaction pathway are shared with candidate
genes identified in either CAMs or antigen processing
and presentation pathways, whereas all candidates
identified in the antigen processing and presentation
pathway are also found in the CAMs pathway. Given
the complex nature of RA, it is not surprising that
many genes and biological pathways contribute to the
pathogenesis of RA [85]. Complimenting evidence from
individual candidate gene lists with biological informa-
tion available through interaction and pathway data-
bases may help identify new targets for therapeutic
treatments of complex diseases such as RA. In spite of
this, additional work utilising other high-throughput
technologies (e.g. RNA-seq and proteomics) and in vivo
models is still required to fully understand the onset
and severity of CIA and ultimately RA.
Conclusions
We report the significant expansion of the MGP re-
source to incorporate deep whole-genome sequencing of
36 inbred laboratory strains. The amount of SNP
variation found has increased from 56 M to 71 M sites,
comparable in genetic variation to the final 1000
Genomes set [86]. In this paper, we focus on the 13 new
laboratory strains that include further representatives of
the classical laboratory and wild-derived strains. The
original project sought to sequence as widely possible
from the laboratory mouse subspecies groups. These 13
new strains mean that we now have several examples of
highly related pairs of strains that are known to display
divergent phenotypes, which could accelerate the identi-
fication of causative variants.
We focus on two specific examples of how the vari-
ation data detected can be used to prioritise genes of
interest for well-known phenotypes in the new strains.
In the first example, we focus on the RF/J strain which
has a highly penetrant predisposition to develop acute
myeloid leukaemia, thymic lymphoma and reticulum cell
Table 4 Significantly over-represented biological pathways and candidate genes identified in DBA/1J
Pathway name Database p value (corrected) Candidate genes
Cell adhesion molecules (CAMs) KEGG 3.98 × 10–4 Esam, H2-M10, H2-M10, H2-T22, Itga9, Sdc3
Type I diabetes mellitus KEGG 7.54 × 10–3 H2-M10, H2-M10, H2-T22
Graft-versus-host disease KEGG 7.59 × 10–3 H2-M10, H2-M10, H2-T22
Autoimmune thyroid disease KEGG 8.55 × 10–3 H2-M10, H2-M10, H2-T22
Allograft rejection KEGG 1.01 × 10–2 H2-M10, H2-M10, H2-T22
Antigen processing and presentation KEGG 1.06 × 10–2 H2-M10, H2-M10, H2-T22
Viral myocarditis KEGG 1.14 × 10–2 H2-M10, H2-M10, H2-T22
Endocytosis KEGG 3.07 × 10–2 Arap3, H2-M10, H2-M10, H2-T22
Linoleic acid metabolism KEGG 4.49 × 10–2 Cyp2c44, Cyp2c50
Cytokine-cytokine receptor interaction KEGG 4.73 × 10–2 Il10ra, Il28ra, Tnfrsf1b, Tnfrsf8
Candidate genes are genes that are found in the over-represented pathways and which contained a missense, deleterious SNP found in DBA/1J and not in DBA/2J or
FVB/NJ. Corrected p values were calculated using the Benjamini–Hochberg method
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sarcomas. We used the expanded variation catalogue to
identify candidate genes containing missense mutations
that are private to the RF/J strain. Several notable genes
with a known role in cancer were identified in our
candidate gene set (e.g. Msh3, Kit, Fas). This gene set
was then further interrogated leading to the identifica-
tion of biological pathways with potential roles in cancer
susceptibility in this strain. In the second analysis, we in-
vestigate the genetic basis of collagen induced arthritis
(a model of human rheumatoid arthritis) using two gen-
etically very similar strains with divergent phenotypes of
susceptible (DBA/1J) and resistant (DBA/2J). Through
comparison of variants identified in both strains, we
were able to identify a candidate gene set of 101 genes
involved in the susceptibility of DBA/1J to this induced
phenotype. Further analysis of this gene set revealed sev-
eral biological processes involved in immune signalling
and inflammation which may play a role in the patho-
genesis of human RA. When using the mutation cata-
logues for genetic mapping studies, it must be noted
that the structural variation calls have an error rate of
up to 10 %. A recent study found that more accurate
structural variation calls can be derived from long read
technologies compared to those produced by short read
detection methods [87], therefore we expect that future
releases of variants on these strains will be even more
accurate.
These strains represent a significant increase in the
disease models available in the MGP variation catalogue
which will enable improved dissection of the genetic
variation underlying many human diseases. The expan-
sion of the catalogue of sequenced strains means that we
can identify mutations that are more likely to be truly
private to individual strains, thereby reducing the size of
candidate variant sets. Sequencing of genetically diverse
strains, such as the wild-derived MOLF/EiJ, are invalu-
able resources for identifying new genetic variation not
present in classical inbred laboratory strains. However,
in wild-derived strains many loci are composed of novel
alleles and divergent haplotypes from the current refer-
ence genome [88]. Efforts are currently ongoing to
create de novo assembled genomes for several classical
and wild-derived strains [89] which will enable more
accurate examination of the genomic structure and
genetic variation responsible for phenotypes observed in
these strains.
Methods
DNA sequencing and read alignment
DNA from a single male of each inbred mouse strain
was obtained from the Jackson Laboratories. Jackson
Laboratory stock numbers for each strain are contained
in Table S1 of Additional file 1. DNA was sheared to
200–300 bp fragment size using a Covaris S2. A single
Illumina TruSeq v3 sequencing library was created for
each strain according to manufacturer’s protocols. Each
library was sequenced on a HiSeq 2000 over four lanes.
Each lane was genotype checked using Samtools/
Bcftools v1.2 (http://www.htslib.org) ‘gtcheck’ command
by comparing variant sites against the mouse Hapmap
[22]. Library and sequencing statistics for each sample
are available in Table S3 of Additional file 1.
Sequencing reads from each lane were aligned to the
C57BL/6 J GRCm38 (mm10) mouse reference genome
[5] using BWA-MEM (v0.7.5) [90] with default parame-
ters. For each library, aligned reads from each lane were
merged using Picard Tools (v1.64) [91], resulting in a
single BAM file corresponding to all aligned reads for a
single strain. Each BAM file (one for each strain) was
then sorted and filtered for possible PCR and optical
duplicates using Picard Tools (v1.64). To improve SNP
and indel calling, the GATK v3.0 ‘IndelRealigner’ tool
[92], was used to realign reads around indels using
default options.
SNP and indel discovery
SNPs and indels were identified using a combination of
SAMtools mpileup (v1.1) [93] and BCFtools call (v1.1).
SAMtools mpileup captures summary information from
input BAMs and uses alignment information to estimate
genotype likelihoods. BCFtools, based on the VCFtools
package [94], then uses this information, with the inclu-
sion of a prior, to perform the variant calling. The
following options were specified for SAMtools; ‘-t
DP,DV,DP4,SP,DPR,INFO/DPR -E -Q 0 -pm3 -F0.25
-d500’ and BCFtools call; ‘-mv -f GQ,GP -p 0.99’. To
improve accuracy of indel calls, indels were then left-
aligned and normalised using the bcftools norm function
with the parameters ‘-D -s -m + indels’.
To ensure high quality variants were only used for
later analysis, bcftools annotate was used to soft filter
SNPs and indels identified. These filters are used to
identify low quality variant calls and remove false
SNP and indel calls due to alignment artifacts. Only
high quality (i.e. passed all filters) homozygote vari-
ants were retained. Filter values and cutoffs used to
identify low quality variants are described in Table S4
of Additional file 1.
SNP and indel annotation and prediction of
consequences
Using mouse gene models obtained from Ensembl 78,
the Ensembl VEP tool (version 78) [23] was used to pre-
dict the effect of SNPs and indels on gene transcripts.
VEP assigns variants to functionally relevant categories
based on the predicted effect that a variant has on a tran-
script or gene. Consequences assigned to variants within
coding regions of a gene include stop losses/gains,
Doran et al. Genome Biology  (2016) 17:167 Page 11 of 16
missense variants and splice variants. Notably, a single
variant may have different estimated consequences be-
tween alternative transcripts of the same gene. To predict
whether amino acid substitutions would be damaging,
GMS [29] were calculated for each variant. GMS are used
to predict the effect of substitutions between amino acids.
Variants with a calculated GMS between 100 and 150
(100 <GMS ≤ 150) were considered moderately radical
and variants with a GMS > 150 were considered radical
changes. Additionally, SIFT [95] scores were estimated for
all variants. SIFT predicts amino acid substitution effects
on protein function and classifies variants as being either
tolerated or deleterious.
Structural variation calling
A combination of BreakDancer [96], cnD [97] and LUMPY
[98] were used to identify larger structural deletions/losses
(greater than 100 bp). BreakDancer identifies large dele-
tions using deviations from the expected mate pair dis-
tance and cnD identifies losses of genomic segments using
changes in mapping depth across regions. LUMPY utilises
multiple SV signals, including read-pair and split-read in-
formation to identify potential SV breakpoints. All parame-
ters used by BreakDancer, cnD and LUMPY are described
in Table S5 of Additional file 1. The deletion call sets for
each strain were then collapsed into strain-specific non-
redundant sets of deletions by merging deletions with a
reciprocal overlap greater than 90 %. This meant that for
each merged deletion there were two possible deletion
breakpoints, the primary breakpoints, which are those
identified by BreakDancer, cnD or LUMPY, and a second-
ary breakpoint, which are the outer bounds of merged
deletions.
To identify SV insertions, RetroSeq (transposable elem-
ent insertions) [99], cnD (copy number gains) [97], scalpel
[100] and manta (both novel sequence insertions) [101]
were used. Parameters for each analysis are contained in
Table S5 of Additional file 1.
Calls made by each tool were then filtered to remove
any SV within 500 bp of an assembly gap or 20 kb of a
telomere or centromere as mapping artifacts in these
regions can cause false SV calls. Additionally, SVs greater
than 1 MB in size were removed as these were generally
false positive calls due to poor mapping among reads.
Identification and count of private variation
Variants identified in the 13 strains examined in this
study were then incorporated in the mouse genomes
variation catalogue. The MGP variation catalogue now
contains variants identified in 36 different inbred labora-
tory mouse strains. To obtain a list of high confidence
variants private to each strain, sequencing data from the
remaining 23 strains contained in the MGP variation
catalogue was aligned to the mouse reference genome
using the same pipeline as described above.
Similarly, the same SAMtools and BCFtools pipeline
as above was used to identify SNPs and short indels.
SNP and indel locations from all 36 strains were collated
into a single file which was used to generate genotypes
at those locations in all strains using samtools mpileup
with the -l option enabled (i.e. report the genotype at all
locations listed). The same bcftools call parameters as
the initial variant calling step were used. This allowed
the identification of high quality homozygous reference
locations, as well as low quality regions and regions with
no sequence information (uncallable regions).
Private SNPs were identified as locations in which a
single high quality homozygote alternative variant was
called in only one of the 36 strains. In the remaining 35
strains, the location must be a high quality homozygous
reference genotype allowing a maximum of five low
quality or missing genotypes in any of the strains. Simi-
larly, private indels were identified for each strain. A pri-
vate indel was defined as any high quality homozygote
alternative indel unique to a single strain.
To identify SV deletions that may be the result of the
same ancestral event, deletions were first identified in
each of the remaining 23 MGP strains using the same
approach as described above. Deletions identified in each
individual strain were compared with the deletions
identified in all other strains (13 strains sequenced as
part of this study and the additional 23 MGP strains). A
non-redundant across-strain deletion set was identified,
as before, using a greater than 90 % reciprocal overlap to
merge deletions. Following this merge, private SV
deletions were identified as those that did not overlap
with another deletion, and thus were not merged with
any other deletion.
Similarly, as with predicted SV deletions, SV insertions
were identified for all 36 strains contained in the MGP
variation catalogue, including the 13 strains from this
study. The insertion call sets for each strain were then
merged and used to identify insertions private to each
strain.
Variants calls accuracy
To assess the accuracy of SNP calls made for each strain,
genotypes were obtained from the mouse HapMap
resource [22] for each of our strains and compared with
the corresponding SNP identified in our catalogue for
each of the 13 strains separately. The mouse HapMap
contains approximately 138,000 homozygous sites geno-
typed in 94 inbred laboratory mouse strains. Genotype
locations for each of the 13 strains were mapped from
mm9 to mm10 of the reference genome, and any
missing genotypes were removed from further analysis.
Between 115,572 (MOLF/EiJ) and 129,825 (C58/J)
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remained after mapping SNP locations from mm9 to
mm10 and removing missing genotypes. Sensitivity of
the SNP calling pipeline was estimated by calculating
the number of genotypes concordant between the
HapMap and the variation catalogue for each of the 13
strains. The number of genotypes from the HapMap
available for comparison with each of the 13 strains
and the respective concordance rate are contained in
Additional file 4.
A dataset of PCR validated SV insertions and deletions
for seven MGP strains (AKR/J, A/J, BALB/cJ, DBA/2J,
CBA/J, C3H/HeJ and LP/J) were obtained from Yalcin
et al. [39]. Coordinates for all variants were first mapped
from NCBIm37 to GRCm38. Using the SV calling pipeline
described above, sequencing data for these seven strains
was used to call structural variants that could be compared
to the PCR-validated set to assess the accuracy of our SV
calling pipeline. In addition, SVs identified in the DBA/1J
from our study were compared to the PCR-validated
variants for DBA/2J (Table S2 of Additional file 1).
Identification of candidate genes through prioritisation of
damaging SNPs
To demonstrate the usefulness of this data, two studies
investigating the genetic basis of cancer susceptibility
and CIA were carried out. The first investigation in-
volved identifying all genes that contained a missense
variant that was private to the RF/J strain. This strain is
an important model used to investigate the onset and
progression of several cancers including leukaemia and
reticulum cell sarcomas. This gene set was then used to
identify any biological pathways that may be enriched
for genes from this set (described below).
The second investigation was carried out to investigate
the genetic basis of CIA. Two strains, DBA/1J and DBA/
2J, were chosen as they are genetically similar (>90.72 %
of DBA/1J SNPs are shared with DBA/2J) but phenotyp-
ically divergent for susceptibility to CIA; DBA/1J is
susceptible, however DBA/2J is resistant. All SNPs iden-
tified in these two strains were collated into a single file.
The SNPs specific to DBA/2J or shared with DBA/2J
were then removed leaving a DBA/1J-specific set of
SNPs. However, these strains differ at the MHC locus.
To account for the differing MHC alleles, SNPs shared
with the CIA-resistant FVB/NJ strain were also removed.
This SNP set was then filtered to only include missense
SNPs with a SIFT annotation of deleterious. All genes
containing these variants were then identified, and this
gene set was used to identify biological pathways that
may be involved in CIA susceptibility.
Pathway over-representation analysis
For each of the candidate gene sets described above, a
pathway over-representation analysis was performed to
identify biological pathways or processes that are statisti-
cally enriched for this gene set. This was done using the
pathway over-representation tools available from Inna-
teDB [66] and analysed pathway annotations available
from the REACTOME [64] and KEGG [65] databases.
This test was based on the hypergeometric algorithm and
correction of p values was done using the Benjamini–
Hochberg method. Significantly over-represented path-
ways were defined as those with a corrected p < 0.05.
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